Skip to main content

Aptiom Disease Interactions

There are 5 disease interactions with Aptiom (eslicarbazepine).

Major

Anticonvulsants (applies to Aptiom) depression

Major Potential Hazard, Moderate plausibility.

Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
  2. "Product Information. Depakene (valproic acid)." Abbott Pharmaceutical (2001):
  3. "Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical (2001):
  4. "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome (2001):
  5. "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
  6. "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals (2001):
  7. "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):
  8. "Product Information. Banzel (rufinamide)." Eisai Inc (2008):
  9. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):
View all 9 references
Major

Anticonvulsants (applies to Aptiom) liver disease

Major Potential Hazard, Moderate plausibility.

Most anticonvulsants are primarily metabolized by the liver. Metabolic activity may be decreased in patients with liver disease, resulting in elevated drug levels and increased risk of toxicity. Therapy with anticonvulsants should be administered cautiously in patients with mild and moderate liver impairment. Therapy with these drugs is mostly not recommended in patients with severe liver impairment. Caution is also advised when treating patients with a history of liver disease, since the use of some anticonvulsants has been associated with hepatotoxicity. Baseline and periodic evaluation of liver function is recommended. Therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
  2. "Product Information. Banzel (rufinamide)." Eisai Inc (2008):
  3. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):
  4. "Product Information. Oxtellar XR (oxcarbazepine)." Supernus Pharmaceuticals Inc (2014):
View all 4 references
Major

Anticonvulsants (applies to Aptiom) renal dysfunction

Major Potential Hazard, Moderate plausibility.

Most anticonvulsants are primarily excreted by the kidney. The plasma clearance may be decreased and the half-life prolonged in patients with impaired renal function. Therapy with anticonvulsants should be administered cautiously in patients with significant renal dysfunction. In most cases it is recommended to adjust the dosage in patients with CrCl <50 mL/min to half the usual starting dose and then increase slowly to achieve the desired clinical response. The renal function should be monitored regularly in patients receiving therapy.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
  2. "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals (2001):
  3. "Product Information. Banzel (rufinamide)." Eisai Inc (2008):
  4. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):
View all 4 references
Moderate

Anticonvulsants (applies to Aptiom) hyponatremia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypothyroidism, Congestive Heart Failure, Adrenal Insufficiency, SIADH

Some anticonvulsants can cause clinically significant hyponatremia (Na < 125 mmol/L). Therapy with these drugs should be administered cautiously in patients with conditions predisposing to hyponatremia, such as SIADH, use of diuretics or drugs associated with inappropriate antidiuretic hormone secretion, adrenal insufficiency, hypothyroidism, primary polydipsia, and edema (e.g., due to liver cirrhosis, congestive heart failure, or nephrotic syndrome). Serum sodium levels should be monitored during maintenance therapy, and patients should be monitored for signs and symptoms possibly indicating hyponatremia such as nausea, malaise, headache, lethargy, confusion, obtundation, and increase in seizure frequency or severity. If hyponatremia occurs, conservative measures such as fluid restriction, a reduction in dosage, or discontinuation of therapy will usually suffice.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
  2. "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals (2001):
  3. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):
Moderate

Eslicarbazepine (applies to Aptiom) thyroid function tests

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thyroid Disease

Dose-dependant decreases in thyroid function tests (serum T3 and T4) have been observed in patients taking eslicarbazepine. These changes were not associated with other abnormal thyroid function tests suggesting hypothyroidism. Abnormal thyroid function should be evaluated and clinicians should be cognizant of these effects when prescribing or administering eslicarbazepine therapy to patients with thyroid disorders.

References

  1. "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):

Aptiom drug interactions

There are 506 drug interactions with Aptiom (eslicarbazepine).

Aptiom alcohol/food interactions

There is 1 alcohol/food interaction with Aptiom (eslicarbazepine).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.